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Kim et al [1] showed interesting results that tacrolimus
and low-dose prednisolone therapy induced complete remis-
sion rapidly and effectively in adult patients with minimal
change disease (MCD). MCD has been regarded as an immu-
nological disorder. Recent works, however, have dramatically
enhanced the understanding of podocyte biology, which may
be the mainstay involved in the pathogenesis of MCD, and
many treatment options that were thought to work via
immunosuppressive pathways are now known to have a
direct nonimmunological effect on the podocyte [2]. Calci-
neurin inhibitors are frequently used to treat relapsing or
resistant nephrotic syndrome [3]. There are several issues to
be resolved, however, before taking tacrolimus as ﬁrst-line
therapy in adults with MCD.
Despite its recognized efﬁcacy, there are still limited data
on the renal histological changes that occur with tacrolimus
therapy. Histological nephrotoxicity of tacrolimus has been
well established in patients with nephrotic syndrome [4].
Previous studies suggested the lowest possible dose of tacro-
limus be used in children with steroid-dependent or steroid-
resistant nephrotic syndrome [5]. Kim et al treated patients
with 0.05 mg/kg of tacrolimus as a ﬁxed dose. Only one
patient was treated with a lower dosage. The optimal dose
of tacrolimus for inducing complete remission of adult MCD is
the ﬁrst question to be answered. There would be individual
differences in the trough level of tacrolimus because of
pharmacogenomics. To prevent toxicity, dose adjustment is
necessary according to the trough level of tacrolimus [5].
Kim et al treated patients with 0.05 mg/kg of tacrolimus for
16 weeks. It is necessary to establish the ideal duration of
tacrolimus therapy for the treatment protocol, addressing when
its tapering begins. It is currently unknown whether complete
discontinuance of all immunosuppressants is preferable to their
long-term continuation at a low dosage. The ideal length of
tacrolimus therapy is the second question to be answered [6].
Although this pilot trial included a small number of patients
over a short period of time, tacrolimus produced a reliable,
beneﬁcial effect in adults with steroid-resistant or steroid-
dependent MCD. Further investigations on a larger number of
patients over longer follow-up periods are required to evaluate
the clinical efﬁcacy and effectiveness (including relapse rates
and side effects) of tacrolimus in adult patients with MCD.132/$ - see front matter & 2012. The Korean Society of Nephrology. P
nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Thank you for your interest in our manuscript. First of all,
the tacrolimus was not stopped after remission but the
dosage was tapered down over various time-periods. As you
mentioned, the adequate dosage and duration of tacrolimus
for the treatment of minimal change lesion (MCD) are still
being debated. We checked the trough level of tacrolimus
during our study to monitor the toxicity as a protocol and got a
mean level of 5.9972.63 (0.3–12.3) ng/mL, which was variable
from patient to patient. The higher trough level did not give
a guarantee of remission, and patients with a lower trough
level also effectively achieved remission. In a small, open,
prospective cohort study with tacrolimus for MCD patients,
the authors maintained low-dose prednisolone (0.5 mg/kg/day)ublished by Elsevier. This is an open access article under the CC BY-NC-
Ho Jun Chin / Letter and Reply258and tacrolimus (0.05 mg/kg/day) for 24 weeks and followed
patients for 23.0 months after cessation of tacrolimus [1]. During
the observation period after the discontinuation of tacrolimus,
50% of patients (6/12 patients) remained in remission.
In this study, we did not plan to show the efﬁcacy of
tacrolimus to maintain remission in MCD and used a ﬁxed
dose of this drug. We cannot therefore suggest an appropriate
schedule of tacrolimus for use in patients with MCD. We need
well-designed clinical studies in the near future to determine
the veriﬁed duration and dosage of tacrolimus to treat MCD.Conﬂict of interest
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